Credit ratings agency, India Ratings and Research (Ind-Ra) in its latest report has projected that the revenue of India’s pharmaceutical market (IPM) rose 16.1% yoy during June 2022, on the back of strong revenue growth across acute and chronic therapy segments namely gastro-intestinal (GI), analgesics, central nervous system (CNS), derma and gynaec therapy products.
According to the report, strong volume growth were observed in key therapies of the IPM. During FY22, IPM had witnessed 15% yoy sales growth, higher than 8%-10% observed over FY18-FY22, aided by the base effect. The rating agency expects mid-to-high single digit growth for IPM during FY23, led by the price hikes (up to 10%) to be taken by players in line with Wholesale Price Inflation index during April-May 2022.
Ind-Ra further noted that IPM reported 2% yoy sales growth during Q1FY23, led by CNS, derma and gynaec segments. During June 2022, sales volumes grew 9.3% yoy (May 2022: down 6.6% yoy), price growth was 6.2% yoy (5% yoy) while the growth in products launches was negative 1.1% yoy (negative 1.7% yoy).
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: